This article is from the source 'independent' and was first published or seen on . It last changed over 40 days ago and won't be checked again for changes.

You can find the current article at its original source at http://www.independent.co.uk/news/business/news/shire-shares-crash-as-american-bidder-abbvie-reassesses-takeover-bid-9795830.html

The article has changed 2 times. There is an RSS feed of changes available.

Version 0 Version 1
Shire shares crash as American bidder AbbVie reassesses takeover bid Shire shares crash as American bidder AbbVie reassesses takeover bid
(about 14 hours later)
Shares in drugs maker Shire plunged 26 per cent in London trading after American bidder AbbVie said it could walk away from a $55 billion (£34.54 billion) takeover bid because of changes to tax rules in the States. Shares in the London-listed drugs maker Shire plunged 22 per cent after its US suitor AbbVie said it could walk away from a $55bn (£34bn) takeover bid because of changes to tax rules in the States.
Shire could become the first victim of new laws ordered by President Obama last month to stop US companies using so-called inversion takeovers to slash their corporate tax bills. Shire could become the largest victim so far of new laws ordered by President Barack Obama last month to stop US companies using so-called inversion takeovers to slash their corporate tax bills.
AbbVie said its board will meet by next Monday to “reconsider” the deal with particular consideration of the “US Treasury’s proposed unilateral changes to the tax regulations”.AbbVie said its board will meet by next Monday to “reconsider” the deal with particular consideration of the “US Treasury’s proposed unilateral changes to the tax regulations”.
The stock market very clearly decided that the deal will be called off with Dublin-domiciled Shire’s shares sliding 1291p to 3849.5p. They had been as high as 5455p at the start of last month and are now back to pre-bid levels. The stock market very clearly decided that the deal will be called off, with Shire’s shares sliding 1,128p to 4,012p. They had been as high as 5,455p at the start of last month and are now back to pre-bid levels.
But Shire fought back sharply saying it believed “AbbVie should proceed with the recommended offer on the agreed terms”. It also pointed out that AbbVie would have to pay a $1.6 billion break fee if it pulled out. But Shire hit back, saying it believed “AbbVie should proceed with the recommended offer on the agreed terms”. It also pointed out that AbbVie would have to pay a $1.6bn break fee if it pulled out.
Earlier this month US drugs firm Salix pulled out of a merger with Italy’s Cosmo. Today, AstraZeneca which had been targeted by Pfizer in an inversion deal, saw its shares drop 3%. Another potential target, artificial-joints maker Smith & Nephew, was down 2 per cent. Shire also said it had not been given a “detailed an-alysis of AbbVie’s tax as- sumptions” and noted that the US firm had not quantified the impact of the change in its announcement.
Although Shire is currently domiciled in Dublin for tax reasons, AbbVie had planned to move the tax base to the UK. The Chicago-based group was also keen to buy Shire in order to diversify its drug portfolio, as its blockbuster anti-arthritis drug Humira is due to come off patent in the US in 2016. Shire specialises in drugs for attention deficit disorder as well as rare diseases.
Earlier this month the US drugs firm Salix pulled out of a merger with Italy’s Cosmo. Today, AstraZeneca, which had been targeted by Pfizer in an inversion deal, saw its shares drop more than 3 per cent, as analysts warned it was a bad sign for a deal.
“If Pfizer doesn’t get the full benefit of lower taxes, they should reduce their price, and that’s something Astra will never accept. These new inversion rules are definitely a negative,” Odile Rundquist, at Helvea, told Bloomberg.
Another potential target, artificial-joints maker Smith & Nephew, fell by 5 per cent.